Aprea Therapeutics, Inc.
APRE • NASDAQ
Aprea Therapeutics, Inc. is a biotechnology company in the healthcare sector trading on NASDAQ, led by CEO Oren Gilad, with a market cap of $7.8M.
CEOOren Gilad
Next Earnings
Upcoming earnings announcement for Aprea Therapeutics, Inc.
Date
Wednesday, May 13, 2026 (in a month)
Timing
Before Market Open (8:00 AM New York)
Fiscal Period
Q1 2026
EPS Estimate
-$0.23
Earnings History
Past 12 earnings reports for Aprea Therapeutics, Inc.
| Date | Period | EPS | EPS Surprise | Revenue | Rev. Surprise | Filing |
|---|---|---|---|---|---|---|
| Mar 16, 2026 | Q4 2025 | -$0.32Est: -$0.37 | +13.5% | $3.3K | — |  10-K |
| Nov 12, 2025 | Q3 2025 | -$0.47Est: -$0.10 | -370.0% | $1.8K | — | 10-Q |
| Aug 12, 2025 | Q2 2025 | -$0.53Est: -$0.31 | -71.0% | $118.1K | — | 10-Q |
| May 14, 2025 | Q1 2025 | -$0.66 | — | $162.5K | — | 10-Q |
| Mar 25, 2025 | Q4 2024 | -$0.49Est: -$0.68 | +27.9% | $205.8KEst: $450.0K | -54.3% | 10-K |
| Nov 7, 2024 | Q3 2024 | -$0.64Est: -$0.72 | +11.1% | $354.6KEst: $225.0K | +57.6% | 10-Q |
| Aug 12, 2024 | Q2 2024 | -$0.58Est: -$0.64 | +9.4% | $561.6KEst: $50.0K | +1023.1% | 10-Q |
| May 14, 2024 | Q1 2024 | -$0.67Est: -$0.78 | +14.1% | $380.6K | — | 10-Q |
| Mar 26, 2024 | Q4 2023 | -$0.92Est: -$0.77 | -19.5% | $14.1KEst: $110.0K | -87.2% | 10-K |
| Nov 9, 2023 | Q3 2023 | -$0.86Est: -$1.16 | +25.9% | $319.5KEst: $80.0K | +299.3% | — |
| Aug 10, 2023 | Q2 2023 | -$0.87Est: -$1.42 | +38.7% | $249.7K | — | 10-Q |
| May 15, 2023 | Q1 2023 | -$1.34 | — | - | — | — |